Researchers demonstrated that biodegradable microneedle patches can deliver pain-relief drugs through pig skin.
The FDA has approved the subcutaneous administration of a fixed combination of amivantamab (Rybrevant; Johnson & Johnson) and a recombinant human hyaluronidase for patients with non–small cell lung ...
The FDA approves a new subcutaneous formulation of amivantamab, enhancing treatment for advanced lung cancer with reduced administration time and improved safety.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback